Furthermore, high levels of TGFβ within the tumor microenvironment sustain CD73 expression in tumor-infiltrating T cells, resulting in high levels of adenosine-dependent immunosuppression and subsequent resistance to anti-CD137 therapies [95]. Here, TNFRSF9 is linked to neoplasm.